Performance and Safety of MUCOGYNE® Ovule as a Moisturizer

Inclusion Criteria:

Women with the following conditions:

• ≥ 18 years of age at inclusion with vaginal dryness, irrespective of the cause (which may or may not be accompanied by irritation of the vulva, discomfort, oritchiness) : women who suffer pain during sexual intercourse, women taking the minipill, mothers during breastfeeding, menopausal women and women taking anti-acnetreatment.

• Having a Vaginal Health Index Score (VHIS) <15 associated to pain and/or dyspareuniafeeling.

• If the patient has reproductive potential, she must be willing to use effectivemethod of contraception (oral contraceptive, intrauterine device, subcutaneouscontraceptive implant, vaginal ring, and condom).

• Patient agrees to not use any local oestrogens, or other vaginal product during thestudy

• Patient agrees to not modify their intimate hygiene and lubricant products

• Patient able to understand and sign the informed consent form before beginning anystudy procedure

• Patient able to comply with study requirements, as defined in the protocol.

• Patient affiliated to a health social security system.

Exclusion Criteria:

Women with the following conditions:

General criteria:

• Pregnant women (patient of childbearing potential must not be pregnant and mustagree to avoid pregnancy during the study by using an effective birth control methodfrom at least one month before D0 (V1) and throughout the duration of the study)

• Patient participating at the same time in another interventional trial within thefour previous weeks and during the study period, being in an exclusion period for aprevious study

• Patient deprived of freedom by administrative or legal decision or underguardianship

• Patient in a social or sanitary establishment

• Patient suspected to be non-compliant according to the investigator's judgment

• Patient in an emergency situation

Criteria related to patient's status:

• Patient with known hypersensitivity to one of MUCOGYNE® Ovule components

• Patient with a known vaginal pathology (clinical diagnosis only) other than vaginaldryness/atrophy

Criteria related to previous or ongoing treatments:

• Patient with a condition or receiving a medication which, in the investigator'sjudgment, put the patient at undue risk

• Patient suffering from systemic diseases and/or using concurrent therapy that mayinterfere with the evaluation of the study results

• Patient undergoing a topical treatment on the test area or a systemic treatment suchas:

• corticosteroids during the 2 previous weeks and during the study

• retinoids and/or immunosuppressors during the 1.5 previous months and duringthe study

• Patient having started or changed her oral contraceptive or any other hormonaltreatment during the three previous months